Seeking Alpha

Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials...

Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY.
Comments (3)
  • p1llmann
    , contributor
    Comment (1) | Send Message
     
    No, No, NO!!! Merck Serono is NOT a division of Merck (MRK) in the USA. It is a division of Merck KGaA in Germany. Everytime I see this simple, stupid mistake, I question the accuracy of anything in the article.
    16 May 2013, 02:18 PM Reply Like
  • biochemist
    , contributor
    Comments (483) | Send Message
     
    Absolutely correct p1llmann. This specific error happens over and over on SA. I would think that the editors would be aware of this issue by now.
    16 May 2013, 02:49 PM Reply Like
  • TaiPan
    , contributor
    Comments (559) | Send Message
     
    But is it the death knell for ONTY? Should I give my shares as a birthday present to someone I don't really like? :-)
    16 May 2013, 09:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs